AR102427A1 - Derivados de carbazol inhibidores de quinasas - Google Patents
Derivados de carbazol inhibidores de quinasasInfo
- Publication number
- AR102427A1 AR102427A1 ARP150103455A ARP150103455A AR102427A1 AR 102427 A1 AR102427 A1 AR 102427A1 AR P150103455 A ARP150103455 A AR P150103455A AR P150103455 A ARP150103455 A AR P150103455A AR 102427 A1 AR102427 A1 AR 102427A1
- Authority
- AR
- Argentina
- Prior art keywords
- remainder
- formula
- cyclopropyl
- formulas
- group
- Prior art date
Links
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical class C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 abstract 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- -1 methylpiperazinyl Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068234P | 2014-10-24 | 2014-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102427A1 true AR102427A1 (es) | 2017-03-01 |
Family
ID=54427879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103455A AR102427A1 (es) | 2014-10-24 | 2015-10-23 | Derivados de carbazol inhibidores de quinasas |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US10266491B2 (OSRAM) |
| EP (1) | EP3209651B9 (OSRAM) |
| JP (1) | JP6599983B2 (OSRAM) |
| KR (1) | KR102514914B1 (OSRAM) |
| CN (1) | CN107074804B (OSRAM) |
| AR (1) | AR102427A1 (OSRAM) |
| AU (1) | AU2015335703B2 (OSRAM) |
| BR (1) | BR112017007545A2 (OSRAM) |
| CA (1) | CA2965523A1 (OSRAM) |
| CL (1) | CL2017001001A1 (OSRAM) |
| CO (1) | CO2017004517A2 (OSRAM) |
| CY (1) | CY1122549T1 (OSRAM) |
| DK (1) | DK3209651T3 (OSRAM) |
| EA (1) | EA032361B1 (OSRAM) |
| ES (1) | ES2761903T3 (OSRAM) |
| HR (1) | HRP20192197T2 (OSRAM) |
| HU (1) | HUE048321T2 (OSRAM) |
| IL (1) | IL251798B (OSRAM) |
| LT (1) | LT3209651T (OSRAM) |
| MA (1) | MA40302B1 (OSRAM) |
| ME (1) | ME03754B (OSRAM) |
| MX (1) | MX374724B (OSRAM) |
| MY (1) | MY190568A (OSRAM) |
| PE (1) | PE20171239A1 (OSRAM) |
| PH (1) | PH12017500724B1 (OSRAM) |
| PL (1) | PL3209651T3 (OSRAM) |
| PT (1) | PT3209651T (OSRAM) |
| RS (1) | RS59707B1 (OSRAM) |
| SG (2) | SG11201703187PA (OSRAM) |
| SI (1) | SI3209651T1 (OSRAM) |
| SM (1) | SMT202000035T1 (OSRAM) |
| TN (1) | TN2017000158A1 (OSRAM) |
| TW (1) | TWI676618B (OSRAM) |
| WO (1) | WO2016065236A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107108506B (zh) | 2014-10-24 | 2022-06-21 | 武田药品工业株式会社 | 杂环化合物 |
| SG10201903621SA (en) * | 2014-10-24 | 2019-05-30 | Bristol Myers Squibb Co | Tricyclic atropisomer compounds |
| CN109153680B (zh) * | 2016-07-07 | 2021-04-23 | 株式会社大熊制药 | 4-氨基吡唑并[3,4-d]嘧啶基氮杂双环衍生物及含其的药物组合物 |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| US10807951B2 (en) | 2017-10-13 | 2020-10-20 | The Regents Of The University Of California | mTORC1 modulators |
| CN109053542A (zh) * | 2018-07-25 | 2018-12-21 | 南通大学 | 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法 |
| EP4038059B1 (en) * | 2019-10-04 | 2023-09-20 | Bristol-Myers Squibb Company | Substituted carbazole compounds |
| CN110862396B (zh) * | 2019-11-29 | 2021-06-04 | 浙江工业大学 | 一种吡咯并[3,4-c]咔唑-1,3(2H，6H)-二酮类化合物的合成方法 |
| JP2023521172A (ja) * | 2020-04-10 | 2023-05-23 | ジービー００５， インコーポレイテッド | キナーゼ阻害剤 |
| EP4157446A1 (en) | 2020-06-02 | 2023-04-05 | GB002, Inc. | Kinase inhibitors |
| CN115232061B (zh) * | 2021-09-18 | 2024-01-30 | 山西紫罗蓝新材料科技有限公司 | 一种3-硝基-9-乙基咔唑粗产物的提取工艺 |
| KR20250034121A (ko) * | 2022-07-06 | 2025-03-10 | 비비디온 테라퓨틱스, 인코포레이티드 | Wrn 헬리케이스 억제제를 포함하는 약제학적 조성물 |
| CN120530096A (zh) * | 2022-09-29 | 2025-08-22 | 维维迪昂疗法有限公司 | 作为keap1调节剂的n-丙烯酰吗啉衍生物及其用途 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
| WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| ATE479687T1 (de) | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| SG159549A1 (en) | 2004-11-10 | 2010-03-30 | Cgi Pharmaceuticals Inc | Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| EP1831227B1 (en) | 2004-12-17 | 2013-06-19 | Glenmark Pharmaceuticals S.A. | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| EP1954290B1 (en) | 2005-11-22 | 2012-07-25 | Merck Sharp & Dohme Corp. | Tricyclic compounds useful as inhibitors of kinases |
| CA2663178C (en) | 2006-09-11 | 2016-01-12 | Matrix Laboratories Ltd. | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
| JP2010502751A (ja) | 2006-09-11 | 2010-01-28 | シージーアイ ファーマシューティカルズ，インコーポレイティド | キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法 |
| US20090062251A1 (en) | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| AU2008335761B2 (en) | 2007-12-13 | 2014-04-24 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| US8318132B2 (en) | 2008-02-14 | 2012-11-27 | Siemens Medical Solutions Usa, Inc. | Imaging agents for detecting neurological dysfunction |
| GB0809360D0 (en) | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
| TW201010997A (en) | 2008-06-18 | 2010-03-16 | Pfizer Ltd | Nicotinamide derivatives |
| TWI458721B (zh) | 2008-06-27 | 2014-11-01 | Celgene Avilomics Res Inc | 雜芳基化合物及其用途 |
| EP2151441A1 (en) | 2008-08-06 | 2010-02-10 | Julius-Maximilians-Universität Würzburg | Beta-carbolin-derivates as substrates for an enzyme |
| SG171815A1 (en) * | 2008-12-19 | 2011-07-28 | Bristol Myers Squibb Co | Carbazole carboxamide compounds useful as kinase inhibitors |
| CN101475571B (zh) | 2009-01-21 | 2011-06-22 | 中国药科大学 | β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途 |
| ES2733093T3 (es) | 2009-02-13 | 2019-11-27 | Nextivity Inc | Control remoto para amplificador |
| EP2582668B1 (en) * | 2010-06-16 | 2016-01-13 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| EP2455378A1 (en) | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| CA2817896A1 (en) | 2010-11-15 | 2012-05-24 | Viiv Healthcare Uk Limited | Inhibitors of hiv replication |
| BR112013029620A2 (pt) | 2011-05-17 | 2016-09-06 | Hoffmann La Roche | inibidores de tirosina quinase de bruton |
| BR112014017021A8 (pt) | 2012-01-10 | 2017-07-04 | Nimbus Iris Inc | inibidores de irak e usos dos mesmos |
| JP6139690B2 (ja) | 2012-10-26 | 2017-05-31 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルートンチロシンキナーゼの阻害剤 |
| BR112015031432A2 (pt) * | 2013-06-25 | 2017-07-25 | Bristol Myers Squibb Co | compostos de carbazol carboxamida úteis como inibidores de cinase |
| AR096721A1 (es) * | 2013-06-25 | 2016-01-27 | Bristol Myers Squibb Co | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos |
| SG10201903621SA (en) * | 2014-10-24 | 2019-05-30 | Bristol Myers Squibb Co | Tricyclic atropisomer compounds |
| CN110511209B (zh) | 2014-10-24 | 2022-07-05 | 百时美施贵宝公司 | 可用作激酶抑制剂的吲哚甲酰胺化合物 |
-
2015
- 2015-10-23 HR HRP20192197TT patent/HRP20192197T2/hr unknown
- 2015-10-23 ME MEP-2019-363A patent/ME03754B/me unknown
- 2015-10-23 HU HUE15790408A patent/HUE048321T2/hu unknown
- 2015-10-23 MY MYPI2017701432A patent/MY190568A/en unknown
- 2015-10-23 PT PT157904087T patent/PT3209651T/pt unknown
- 2015-10-23 EA EA201790745A patent/EA032361B1/ru not_active IP Right Cessation
- 2015-10-23 ES ES15790408T patent/ES2761903T3/es active Active
- 2015-10-23 SM SM20200035T patent/SMT202000035T1/it unknown
- 2015-10-23 CN CN201580057722.3A patent/CN107074804B/zh active Active
- 2015-10-23 CA CA2965523A patent/CA2965523A1/en active Pending
- 2015-10-23 KR KR1020177013606A patent/KR102514914B1/ko active Active
- 2015-10-23 AU AU2015335703A patent/AU2015335703B2/en not_active Ceased
- 2015-10-23 TN TN2017000158A patent/TN2017000158A1/en unknown
- 2015-10-23 WO PCT/US2015/057077 patent/WO2016065236A1/en not_active Ceased
- 2015-10-23 JP JP2017522120A patent/JP6599983B2/ja active Active
- 2015-10-23 SI SI201530981T patent/SI3209651T1/sl unknown
- 2015-10-23 RS RS20191645A patent/RS59707B1/sr unknown
- 2015-10-23 AR ARP150103455A patent/AR102427A1/es unknown
- 2015-10-23 DK DK15790408.7T patent/DK3209651T3/da active
- 2015-10-23 BR BR112017007545A patent/BR112017007545A2/pt not_active Application Discontinuation
- 2015-10-23 PE PE2017000741A patent/PE20171239A1/es unknown
- 2015-10-23 LT LTEP15790408.7T patent/LT3209651T/lt unknown
- 2015-10-23 PL PL15790408T patent/PL3209651T3/pl unknown
- 2015-10-23 EP EP15790408.7A patent/EP3209651B9/en active Active
- 2015-10-23 TW TW104134975A patent/TWI676618B/zh not_active IP Right Cessation
- 2015-10-23 MA MA40302A patent/MA40302B1/fr unknown
- 2015-10-23 SG SG11201703187PA patent/SG11201703187PA/en unknown
- 2015-10-23 PH PH1/2017/500724A patent/PH12017500724B1/en unknown
- 2015-10-23 SG SG10201903619YA patent/SG10201903619YA/en unknown
- 2015-10-23 US US15/521,194 patent/US10266491B2/en active Active
- 2015-10-23 MX MX2017005255A patent/MX374724B/es active IP Right Grant
-
2017
- 2017-04-19 IL IL251798A patent/IL251798B/en active IP Right Grant
- 2017-04-21 CL CL2017001001A patent/CL2017001001A1/es unknown
- 2017-05-04 CO CONC2017/0004517A patent/CO2017004517A2/es unknown
-
2019
- 2019-04-10 US US16/289,878 patent/US10676434B2/en active Active
-
2020
- 2020-01-17 CY CY20201100040T patent/CY1122549T1/el unknown
- 2020-04-27 US US16/859,103 patent/US11053197B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102427A1 (es) | Derivados de carbazol inhibidores de quinasas | |
| MX2017005259A (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas. | |
| CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
| CY1124444T1 (el) | Διφθορομεθυλ-αμινοπυριδινες και διφθορομεθυλ-αμινοπυριμιδινες | |
| EA201691579A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| CO2017006214A2 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| AR102361A1 (es) | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| EA201991183A1 (ru) | Новые ингибиторы глутаминазы | |
| MX367713B (es) | Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta. | |
| CL2017000071A1 (es) | Acidos carboxílicos hterocíclicos como activadores de guanilato ciclasa soluble. | |
| AR096721A1 (es) | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos | |
| AR110088A1 (es) | Inhibidores de magl | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| MX387483B (es) | Preparación farmacéutica. | |
| AR098776A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| EA201690012A1 (ru) | Карбазолкарбоксамидные соединения | |
| EA201891379A1 (ru) | Ингибиторы тирозинкиназы брутона и способы их применения | |
| AR105875A1 (es) | Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
| AR102246A1 (es) | Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de osteoporosis, usos | |
| AR101155A1 (es) | Quinazolin-thf-aminas halogenadas como inhibidores de pde1 | |
| CY1120744T1 (el) | Παραγωγα οξικου οξεος αζαϊνδολης και η χρηση αυτων ως ρυθμιστων υποδοχεων προσταγλανδινης d2 | |
| AR102773A1 (es) | Derivados de pirido benzodiazepina sustituidos y su utilización |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |